These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 17457655)

  • 1. Mathematical model of BCG immunotherapy in superficial bladder cancer.
    Bunimovich-Mendrazitsky S; Shochat E; Stone L
    Bull Math Biol; 2007 Aug; 69(6):1847-70. PubMed ID: 17457655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mathematical model of pulsed immunotherapy for superficial bladder cancer.
    Bunimovich-Mendrazitsky S; Byrne H; Stone L
    Bull Math Biol; 2008 Oct; 70(7):2055-76. PubMed ID: 18716846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vaccines and interleukin-12 DNA vaccine.
    Lee CF; Chang SY; Hsieh DS; Yu DS
    J Urol; 2004 Mar; 171(3):1343-7. PubMed ID: 14767345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mathematical model of combined bacillus Calmette-Guerin (BCG) and interleukin (IL)-2 immunotherapy of superficial bladder cancer.
    Bunimovich-Mendrazitsky S; Claude Gluckman J; Chaskalovic J
    J Theor Biol; 2011 May; 277(1):27-40. PubMed ID: 21334346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
    Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
    J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study.
    Yutkin V; Pode D; Pikarsky E; Mandelboim O
    J Urol; 2007 Dec; 178(6):2660-4. PubMed ID: 17945285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacillus Calmette-Guérin immunotherapy for superficial bladder cancer. New prospects for an old warhorse.
    O'Donnell MA; DeWolf WC
    Surg Oncol Clin N Am; 1995 Apr; 4(2):189-202. PubMed ID: 7796280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cytokine therapy of superficial bladder carcinoma. Mechanisms of action and results of therapy].
    Otto T; Kälble T
    Urologe A; 1994 Nov; 33(6):540-6. PubMed ID: 7817454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer.
    Böhle A; Brandau S
    J Urol; 2003 Sep; 170(3):964-9. PubMed ID: 12913751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting bacillus Calmette-Guerin immunotherapy effectiveness.
    Griffith TS
    J Urol; 2007 Dec; 178(6):2247-8. PubMed ID: 17936825
    [No Abstract]   [Full Text] [Related]  

  • 11. Prospects for improving the efficacy of BCG.
    Böhle A
    Eur Urol; 1992; 21 Suppl 2():22-7. PubMed ID: 1396944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunodominant PstS1 antigen of mycobacterium tuberculosis is a potent biological response modifier for the treatment of bladder cancer.
    Sänger C; Busche A; Bentien G; Spallek R; Jonas F; Böhle A; Singh M; Brandau S
    BMC Cancer; 2004 Nov; 4():86. PubMed ID: 15566565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer.
    Demkow T; Alter A; Wiechno P
    Urol Int; 2008; 80(1):74-9. PubMed ID: 18204238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New-onset psoriasis and psoriatic arthritis in a patient treated with Bacillus Calmette-Guérin (BCG) immunotherapy.
    Dudelzak J; Curtis AR; Sheehan DJ; Lesher JL
    J Drugs Dermatol; 2008 Jul; 7(7):684. PubMed ID: 18664162
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunoprotection against murine bladder carcinoma by octaarginine-modified liposomes incorporating cell wall of Mycobacterium bovis bacillus Calmette-Guérin.
    Joraku A; Homhuan A; Kawai K; Yamamoto T; Miyazaki J; Kogure K; Yano I; Harashima H; Akaza H
    BJU Int; 2009 Mar; 103(5):686-93. PubMed ID: 19040525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of target cell infection and natural killer cells in the anti-tumor effects of bacillus Calmette-Guerin in murine bladder cancer.
    Sonoda T; Sugimura K; Ikemoto S; Kawashima H; Nakatani T
    Oncol Rep; 2007 Jun; 17(6):1469-74. PubMed ID: 17487406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses.
    Suttmann H; Riemensberger J; Bentien G; Schmaltz D; Stöckle M; Jocham D; Böhle A; Brandau S
    Cancer Res; 2006 Aug; 66(16):8250-7. PubMed ID: 16912205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.
    Ayari C; LaRue H; Hovington H; Decobert M; Harel F; Bergeron A; Têtu B; Lacombe L; Fradet Y
    Eur Urol; 2009 Jun; 55(6):1386-95. PubMed ID: 19193487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of animal models in understanding intravesical therapy with bacille Calmette-Guérin.
    Ratliff TL
    Clin Infect Dis; 2000 Sep; 31 Suppl 3():S106-8. PubMed ID: 11010834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
    Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
    BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.